Pipeline

Our miRNAs platform try to find new ways to develop therapies against metabolic diseases. Our products have been engineered to change the proteome for specific metabolic enhancing.

Currently, the tumor-targeting strategy for MV is further developed by taking advantage of microRNA techniques (“Targeting 2.0”). We have know-how to introduce MicroRNA synthetic sequences in the viral genome.

Today, our main project is to develop a miRNA against the Cushing syndrome and dysfunctional lipid homeostasis, and drugs who enhance the insulin sensivity.

 

We try to find new pathways to enhance the chemosensitivity in tumors.